Search Results - "Arner, Emily"

Refine Results
  1. 1

    Metabolic programming and immune suppression in the tumor microenvironment by Arner, Emily N., Rathmell, Jeffrey C.

    Published in Cancer cell (13-03-2023)
    “…Increased glucose metabolism and uptake are characteristic of many tumors and used clinically to diagnose and monitor cancer progression. In addition to cancer…”
    Get full text
    Journal Article
  2. 2

    Mutation and tissue lineage lead to organ-specific cancer by Arner, Emily N., Rathmell, W. Kimryn

    Published in Nature (London) (30-06-2022)
    “…Cancer-promoting mutations tend to result in tumours arising only in certain organs, but the reasons for this specificity are not fully understood. The…”
    Get full text
    Journal Article
  3. 3

    Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers by Arner, Emily N, Du, Wenting, Brekken, Rolf A

    Published in Frontiers in oncology (11-10-2019)
    “…Cellular plasticity, a feature associated with epithelial-to-mesenchymal transition (EMT), contributes to tumor cell survival, migration, invasion, and therapy…”
    Get full text
    Journal Article
  4. 4

    AXL Inhibitor TP-0903 Reduces Metastasis and Therapy Resistance in Pancreatic Cancer by Zhang, Yuqing, Arner, Emily N, Rizvi, Ali, Toombs, Jason E, Huang, Huocong, Warner, Steven L, Foulks, Jason M, Brekken, Rolf A

    Published in Molecular cancer therapeutics (01-01-2022)
    “…Pancreatic cancer is the third leading cause of cancer-related deaths in the United States with a 5-year survival less than 5%. Resistance to standard therapy…”
    Get full text
    Journal Article
  5. 5

    Immunometabolism of ferroptosis in the tumor microenvironment by Lupica-Tondo, Gian Luca, Arner, Emily N, Mogilenko, Denis A, Voss, Kelsey

    Published in Frontiers in oncology (12-08-2024)
    “…Ferroptosis is an iron-dependent form of cell death that results from excess lipid peroxidation in cellular membranes. Within the last decade, physiological…”
    Get full text
    Journal Article
  6. 6

    HIF-2α expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma by Bacigalupa, Zachary A, Arner, Emily N, Vlach, Logan M, Wolf, Melissa M, Brown, Whitney A, Krystofiak, Evan S, Ye, Xiang, Hongo, Rachel A, Landis, Madelyn, Amason, Edith K, Beckermann, Kathryn E, Rathmell, W Kimryn, Rathmell, Jeffrey C

    Published in The Journal of clinical investigation (17-06-2024)
    “…Clear cell renal cell carcinoma (ccRCC) is an aggressive cancer driven by VHL loss and aberrant HIF-2α signaling. Identifying means to regulate HIF-2α thus has…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

    Loss of Tbk1 kinase activity protects mice from diet-induced metabolic dysfunction by Cruz, Victoria H., Arner, Emily N., Wynne, Katherine W., Scherer, Philipp E., Brekken, Rolf A.

    Published in Molecular metabolism (Germany) (01-10-2018)
    “…TANK Binding Kinase 1 (TBK1) has been implicated in the regulation of metabolism through studies with the drug amlexanox, an inhibitor of the IκB kinase…”
    Get full text
    Journal Article
  13. 13

    Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer by Cruz, Victoria H, Arner, Emily N, Du, Wenting, Bremauntz, Alberto E, Brekken, Rolf A

    Published in JCI insight (02-05-2019)
    “…Pancreatic ductal adenocarcinoma (PDA) is characterized by an activating mutation in KRAS. Direct inhibition of KRAS through pharmacological means remains a…”
    Get full text
    Journal Article
  14. 14

    Functional Crosstalk between the PP2A and SUMO Pathways Revealed by Analysis of STUbL Suppressor, razor 1-1 by Nie, Minghua, Arner, Emily, Prudden, John, Schaffer, Lana, Head, Steven, Boddy, Michael N

    Published in PLoS genetics (01-07-2016)
    “…Posttranslational modifications (PTMs) provide dynamic regulation of the cellular proteome, which is critical for both normal cell growth and for orchestrating…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    Mutation and lineage lead to organ-specific cancer by Arner, Emily N, Rathmell, W Kimryn

    Published in Nature (London) (30-06-2022)
    “…[...]BRAF mutations are associated with the skin cancer melanoma, APC mutations are a hallmark of colon cancer, and loss of the gene VHL is a characteristic of…”
    Get full text
    Journal Article
  18. 18

    Single-cell transcriptomics of colorectal cancer metastases identifies enrichment for a therapeutically targetable population of TREM2+ macrophages in peritoneal metastases by Cottam, Matthew, Mirza, Muhammad, Arner, Emily, Hatem, Zaid, Shameer, Muhammad, Beckermann, Kathryn, Idrees, Kamran

    Published in The Journal of immunology (1950) (01-05-2024)
    “…Colorectal cancer (CRC) is recognized as the third most common cancer and the second leading cause of cancer-related mortality globally. The primary driver…”
    Get full text
    Journal Article
  19. 19

    Abstract 1033: Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer by Arner, Emily N., Cruz, Victoria H., Du, Wenting, Brekken, Rolf

    Published in Cancer research (Chicago, Ill.) (01-07-2019)
    “…Pancreatic ductal adenocarcinoma (PDA) is characterized by an activating mutation in KRAS. Direct inhibition of KRAS through pharmacological means remains a…”
    Get full text
    Journal Article
  20. 20

    HIF-2α expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma by Bacigalupa, Zachary A, Arner, Emily N, Vlach, Logan M, Wolf, Melissa M, Brown, Whitney A, Krystofiak, Evan S, Ye, Xiang, Hongo, Rachel A, Landis, Madelyn, Amason, Edith K, Beckermann, Kathryn E, Rathmell, W Kimryn, Rathmell, Jeffrey C

    Published in The Journal of clinical investigation (17-06-2024)
    “…Clear cell renal cell carcinoma (ccRCC) is an aggressive cancer driven by VHL loss and aberrant HIF-2α signaling. Identifying means to regulate HIF-2α thus has…”
    Get full text
    Journal Article